arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Protalix BioTherapeutics, Inc.

PLX
$2.45 ▲ +0.01 (+0.20%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Protalix BioTherapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $195.6M
Dividend Yield
Revenue Growth 233.7%
Op. Margin 62.7%
ROIC 27.3%
FCF / Share $0.27
Trailing P/E 10.7x
Price / Book 2.9x
FCF Yield 10.9%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$33.75M
↑ +233.7%
Net Income Profit after all expenses
$18.32M
↑ +432.8%
Operating Margin Operating profit as % of sales
62.7%
↑ +222.7% 15th
FCF / Share Free cash flow per share
$0.27
↑ +599.1%
Long-Term Debt Long-term obligations
$376.00K
↓ -86.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
12
Returns
31
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters